BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US
Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.
Search
Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease – IPF – in Honor of his Dad
Yankees Baseball Legend Bernie Williams Raises Awareness Of Devastating Lung Disease – Ipf – In Honor Of His Dad
Sustainable Development - Our Commitment
Our Commitment
Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US
Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Our Innovation Prize | Partnering
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Fostering Science | Boehringer Ingelheim US
Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.
FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US
FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
New initiative elevates the importance of CKD testing
Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US
FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.
Onboarding
Onboarding
Tomorrow leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Partnering Days
Partnering Days
Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Corporate Social Responsibility | Boehringer Ingelheim US
Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.
PAP Resources
PAP Resources
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Yanina Donatini
Yanina Donatini, Head of ITM&S Content Production at Boehringer Ingelheim speaks about her 20 years in the company as innovative and diverse.